Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic...

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Immune checkpoint inhibitors (CPIs) are effective for solid tumors, especially mismatch repair deficient (MMRd) colorectal cancer (CRC).
• MMRd tumors have high neoantigen burden and activated cGAS-STING pathways, promoting immune surveillance.
• However, primary and acquired resistance to CPIs affects a significant portion of MMRd CRC patients.

Purpose of the Study:

• To review the mechanisms of immune evasion and CPI resistance in MMRd CRC.
• To identify signaling pathways and genetic alterations associated with CPI refractoriness.
• To provide a rationale for developing novel strategies to enhance CPI efficacy in MMRd CRC.

Main Methods:

• Review of clinical sample profiling and preclinical studies.
• Analysis of genetic alterations in Wnt and JAK-STAT signaling pathways.
• Investigation of mutations in antigen presentation machinery (MHC, Beta-2 microglobulin).

Main Results:

• Alterations in Wnt and JAK-STAT pathways are linked to CPI resistance in MMRd CRC.
• Mutations in antigen presentation machinery (e.g., MHC, B2M) contribute to immune evasion but not necessarily CPI response.
• Understanding these resistance mechanisms is crucial for therapeutic development.

Conclusions:

• Despite initial efficacy, resistance to CPIs remains a challenge in MMRd CRC.
• Targeting Wnt and JAK-STAT pathways, alongside understanding immune evasion, offers potential for overcoming CPI resistance.
• Further research into these mechanisms will expand patient benefit from CPI therapy.